Latest Intelligence on Pharmaceuticals and Healthcare in United Kingdom

Published within

« | ... | 4 | 5 | 6 | 7 | 8 | 9 | 10 | 11 | 12 | ... | » »|

Type Product title / description Pub Price
CommentWire
CommentWire

Biocontrol Ltd: novel approach for treatment of Pseudomonas

A small UK company has presented positive results from a Phase II trial investigating the use of bacteriophages for the treatment of Pseudomonas infections. The product, while still in the early stages of clinical development, represents a novel approach to the treatment of bacterial infections and offers a crucial new avenue of research in the treatment of Pseudomonas.

Published By Datamonitor
27 Feb 2008
CommentWire
CommentWire

Biogen-IDEC / Elan: Tysabri affirms its potential

Biogen-IDEC [BIIB] and Elan [ELA.L] have announced that Tysabri has demonstrated significant improvements in disability progression and reduction in the rate of relapse in relapse-remitting multiple sclerosis (RRMS). The outlook for the drug is therefore extremely bright, and it could cannibalize revenues of rival RRMS products significantly. Tysabri may yet herald a new dawn in RRMS treatment.

Published By Datamonitor
18 Feb 2005
ResearchWire
ResearchWire

Bipolar disorders: 6.9 million with disorder in 2008

Published By Datamonitor
06 Aug 2001
CommentWire
CommentWire

Bird flu: current measures may not be enough

Faced by growing fears of a flu epidemic on the scale of those seen in the early twentieth century, the UK Department of Health has confirmed it is drawing up plans to deal with a possible bird flu crisis. Though vaccine manufacturers Chiron and Aventis-Pasteur have announced imminent initiation of human testing for bird flu vaccines, wider issues over prophylactic provision remain.

Published By Datamonitor
15 Dec 2004
CommentWire
CommentWire

BMS/Celltech: a death knell for MMPIs

Lung cancer treatment BMS275291 has been withdrawn from Bristol-Myers Squibb [BMY] and Celltech's [CCH.L] development program due to lack of efficacy. It is another in a string of failures that have beset metalloproteinase inhibitors and signals a death knell for the drug class.

Published By Datamonitor
16 Jun 2003
ResearchWire
ResearchWire

Breast cancer: 463,000 new cases predicted in 2010

Published By Datamonitor
30 Sep 2002
CommentWire
CommentWire

Bristol-Myers Squibb: Orencia is rejected by NICE in the UK

The decision by the National Institute for Health and Clinical Excellence to reject Bristol-Myers Squibb's Orencia has dealt a blow to many rheumatoid arthritis patients in the UK. However, Datamonitor expects that Orencia will overcome this initial upset in the UK and go on to achieve blockbuster status in this indication, driven in particular by strong sales in the US.

Published By Datamonitor
03 Aug 2007
CommentWire
CommentWire

British Biotech: moving away from its disastrous past

The news indicates a further step in British Biotech's slow recovery from the poor performance of marimastat and the recent trial results from its Biodiv Ysio stent. However, the company still needs to find a promotion partner for the new thrombolytic if it is to continue to expand its pipeline.

Published By Datamonitor
27 Mar 2002
CommentWire
CommentWire

Cambridge Antibody Technology: playing catch-up

Published By Datamonitor
23 May 2001
CommentWire
CommentWire

Cancer pain: education is the key

The high level of under-treatment for cancer pain is a result of poor diagnosis, assessment, and treatment by physicians. It is coupled with an unfounded fear of the use of controlled drugs such as opioids. The key to better management of cancer pain is improved educational programs and the development of dedicated pain management teams.<BR />

Published By Datamonitor
27 Mar 2003

« | ... | 4 | 5 | 6 | 7 | 8 | 9 | 10 | 11 | 12 | ... | » »|

No help is available.